Clinical Topics
-
When cisplatin won’t do, try carboplatin in head and neck cancer -
Is early-onset cancer an emerging global epidemic? -
Despite benefits, extended-interval pembro uptake remains low -
Time to cancer diagnoses in U.S. averages 5 months -
Trends in Palliative Care Utilization and Facility Type for Stage IV Esophageal Cancer: A National Cancer Database Analysis
Digital Edition
Conference Coverage
-
Metronomic chemotherapy performs well in second-line head and neck cancer -
Radiofrequency ablation successful in small thyroid cancers -
A farewell to arms? Drug approvals based on single-arm trials can be flawed -
Time to cancer diagnoses in U.S. averages 5 months -
Pembro/chemo combo fails to improve event-free survival in head and neck cancer -
First drug for desmoid tumors: ‘Impressive’ data for nirogacestat -
Collagen ‘tile’ delivers postsurgical radiation in glioblastoma -
Can liquid biopsy predict oropharyngeal cancer recurrence? -
Confirmed: Pembro plus chemo as first-line standard of care for esophageal cancer -
Many patients, doctors unaware of advancements in cancer care
Question 1 of 5
